Analyst Ratings for OrthoPediatrics CHILDREN over the last quarter vary from bullish to bearish, according to 6 analysts.
The table below provides an overview of their recent ratings, showing how sentiments have changed over the past 30 days and comparing them to previous months.
Bullish | A little bullish | Indifferent | A little bearish | Bearish | |
---|---|---|---|---|---|
Total scores | 3 | 1 | 2 | 0 | 0 |
Last 30 days | 1 | 0 | 0 | 0 | 0 |
There are 1 million | 0 | 0 | 0 | 0 | 0 |
There are 2 million | 2 | 1 | 1 | 0 | 0 |
There are 3 million | 0 | 0 | 1 | 0 | 0 |
Analysts have set 12-month price targets for OrthoPediatrics, revealing an average target of $36.83, a high estimate of $50.00, and a low estimate of $31.00. Observing an increase of 8.32%, the current average has increased from the previous average price target of $34.00.
Breaking down analyst ratings: a detailed look
By looking at recent analyst actions, we gain insight into how financial experts view OrthoPediatrics. The following summary features top analysts, their recent ratings, and adjustments to ratings and price targets.
Analyst | Analyst firm | Action taken | Rating | Current price target | Previous price target |
---|---|---|---|---|---|
Mike Matson | Needham | Maintains | Buy | $37.00 | – |
Samuel Brodovsky | Truist Tracks | Increase | Socket | $32.00 | $31.00 |
wise rick | Stifel | Increase | Buy | $34.00 | $32.00 |
Mike Matson | Needham | Maintains | Buy | $37.00 | – |
David Turkaly | JMP Titles | Maintains | Market outperformance | $50.00 | – |
Kaila Krum | Truist Tracks | Lowers | Socket | $31.00 | $39.00 |
Key ideas:
- Action taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they “maintain,” “increase,” or “decrease” their position signifies their reaction to recent developments related to orthopedics. This overview provides insight into the analysts’ outlook on the current state of the company.
- Rating: Providing a holistic view, analysts rate stocks qualitatively, ranging from “outperform” to “underperform.” These ratings reflect expectations regarding OrthoPediatrics’ relative performance compared to the market as a whole.
- Price targets: Analysts run through price target adjustments, providing estimates of OrthoPediatrics’ future value. Comparing current and past targets provides insight into how analyst expectations are changing.
To get a panoramic view of OrthoPediatrics’ market performance, explore these analyst ratings along with key financial metrics. Stay informed and make smart decisions using our scorecard.
Stay up to date on OrthoPediatrics analyst ratings.
If you want to follow the news and performance of small cap stocks you can start by following it here.
About Orthopediatrics
OrthoPediatrics Corp is a medical device company. The Company is engaged in supplying products to the pediatric orthopedic market. The company designs, develops and markets implants and instruments to meet the needs of surgeons and patients. Its products include, among others, PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia and ACL Reconstruction System.
Financial Outlook: Orthopedics
Market capitalization analysis: Falling below industry benchmarks, the company’s market capitalization reflects a reduced size relative to its peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive revenue trend: Examining OrthoPediatrics’ 3-month financial statements reveals a positive story. The company achieved a remarkable revenue growth rate of 21.36% as of December 31, 2023, showing a substantial increase in net profit. Compared to its competitors, the company has exceeded expectations with a growth rate higher than the average of its healthcare industry peers.
Net margin: OrthoPediatrics’ net margin is below industry standards, reflecting the challenges it faces in achieving strong profitability. With a net margin of -17.79%, the company may encounter difficulties in effectively controlling its costs.
Return on Equity (ROE): OrthoPediatrics’ ROE stands out, exceeding industry averages. With an impressive ROE of -1.78%the company demonstrates efficient use of equity and strong financial performance.
Return on assets (ROA): The company’s ROA is below industry benchmarks, signaling potential difficulties in efficient asset utilization. With an ROA of -1.54%, the company may face challenges in generating satisfactory returns on its assets.
Debt Management: With a below-average debt-to-equity ratio 0.03OrthoPediatrics adopts a conservative financial strategy, indicating a balanced approach to debt management.
Analyst Ratings: Simplified
Ratings come from analysts or specialists in banking and financial systems who report on specific stocks or defined sectors (usually once a quarter for each stock). Analysts typically draw their information from company conference calls and meetings, financial statements, and conversations with important insiders to make their decisions.
Analysts can supplement their ratings with forecasts on metrics such as growth estimates, earnings and revenue, providing investors with a more comprehensive outlook. However, investors should keep in mind that analysts, like any human being, can have subjective perspectives that influence their forecasts.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.